| Assessment Status | Rapid Review Complete |
| HTA ID | 24043 |
| Drug | Vibegron |
| Brand | Obgemsa® |
| Indication | Vibegron (Obgemsa®) is indicated for the symptomatic treatment of adult patients with overactive bladder syndrome. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2024 |
| Rapid review completed | 26/11/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that vibegron not be considered for reimbursement at the submitted price*. |
*This recommendation is considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.